|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 1/08/18 Syneos Health, Inc. 8-K:5,7,9 1/04/18 4:156K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 16K 2: EX-3.1 Articles of Incorporation/Organization or By-Laws HTML 9K 3: EX-3.2 Articles of Incorporation/Organization or By-Laws HTML 103K 4: EX-99.1 Miscellaneous Exhibit HTML 13K
| Form 8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 4, 2018
SYNEOS HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 001-36730 | 27-3403111 | |
| (Commission File Number) |
(IRS Employer Identification No.) |
3201 Beechleaf Court, Suite 600, Raleigh, North Carolina 27604-1547
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (919) 876-9300
INC Research Holdings, Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.03. | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On January 4, 2018, Syneos Health, Inc. (the “Company”) filed a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect a change of the Company’s name from “INC Research Holdings, Inc.” to “Syneos Health, Inc.,” effective as of January 4, 2018 (the “Name Change”). The Certificate of Amendment effecting the Name Change is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
Effective January 4, 2018, in connection with the Name Change, the Company also amended and restated its bylaws, by substituting “Syneos Health, Inc.” for “INC Research Holdings, Inc.” in Section 1.01 thereof. The Company’s Amended and Restated Bylaws are filed as Exhibit 3.2 to this Current Report on Form 8-K and incorporated herein by reference.
On January 8, 2018, shares of the Company commenced trading under a new Nasdaq Stock Exchange ticker symbol, “SYNH,” and a new CUSIP number, 87166B102.
| Item 7.01. | Regulation FD Disclosure. |
On January 4, 2018, the Company issued a press release announcing the Name Change. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SYNEOS HEALTH, INC. | ||||||
| Date: January 8, 2018 | ||||||
| Name: | Christopher L. Gaenzle | |||||
| Title: | Chief Administrative Officer & General Counsel | |||||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 1/8/18 | None on these Dates | ||
| For Period End: | 1/4/18 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/16/23 Syneos Health, Inc. 10-K 12/31/22 136:28M Donnelley … Solutions/FA 8/02/22 Syneos Health, Inc. 10-Q 6/30/22 87:12M Donnelley … Solutions/FA 2/17/22 Syneos Health, Inc. 10-K 12/31/21 134:25M ActiveDisclosure/FA 6/04/21 Syneos Health, Inc. 424B7 1:390K Donnelley … Solutions/FA 5/05/21 Syneos Health, Inc. 424B7 1:398K Donnelley … Solutions/FA 3/03/21 Syneos Health, Inc. 424B7 1:405K Donnelley … Solutions/FA 2/18/21 Syneos Health, Inc. 10-K 12/31/20 130:23M ActiveDisclosure/FA 12/03/20 Syneos Health, Inc. 424B7 1:397K Donnelley … Solutions/FA 9/16/20 Syneos Health, Inc. 424B7 1:506K Donnelley … Solutions/FA |